Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis

Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (HCM) patients. Methods: From the inception to...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Open Exploration Publishing Inc. 2026-01-01
Ráidu:	Exploration of Cardiology
Fáttát:	network meta-analysis cardiac myosin inhibitors mavacamten aficamten hypertrophic cardiomyopathy lvot gradient lvef
Liŋkkat:	https://www.explorationpub.com/uploads/Article/A101289/101289.pdf
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!